Marker Therapeutics Sells Subsidiary to Catalent for $1B

TL;DR

Marker Therapeutics selling its subsidiary to Catalent for $1 BILLION cash. Deal expected Q2 2024.

AI Summary

Marker Therapeutics, Inc. announced on March 25, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics LLC, to Catalent, Inc. for approximately $1.0 billion in cash. This transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.

Why It Matters

This significant divestiture allows Marker Therapeutics to focus on its core business and potentially return capital to shareholders, while Catalent expands its cell and gene therapy manufacturing capabilities.

Risk Assessment

Risk Level: medium — The transaction is subject to customary closing conditions and regulatory approvals, introducing a risk of the deal not closing as planned.

Key Numbers

• $1.0B — Sale Price (Marker Therapeutics LLC sold to Catalent, Inc.)
• Q2 2024 — Expected Closing (Subject to customary closing conditions.)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Seller
• Marker Therapeutics LLC (company) — Subsidiary being sold
• Catalent, Inc. (company) — Buyer
• $1.0 billion (dollar_amount) — Sale price
• March 25, 2024 (date) — Announcement date
• second quarter of 2024 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar

Filing Documents

• tm249709d1_8k.htm (8-K) — 24KB
• tm249709d1_ex99-1.htm (EX-99.1) — 105KB
• tm249709d1_ex99-1img001.jpg (GRAPHIC) — 6KB
• 0001104659-24-038533.txt ( ) — 318KB
• mrkr-20240325.xsd (EX-101.SCH) — 3KB
• mrkr-20240325_lab.xml (EX-101.LAB) — 33KB
• mrkr-20240325_pre.xml (EX-101.PRE) — 22KB
• tm249709d1_8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On March 25, 2024, Marker Therapeutics, Inc. (the " Company ") reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated March 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: March 25, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR